Article Sidebar
Views pdf: 225
Views pdf: 33
ASSESSING THE EFFECTIVENESS OF CONCURRENT CHEMORADIOTHERAPY WITH CISPLATIN AND ORAL VINORELBINE IN STAGE III NON-SMALL CELL LUNG CANCER
Main Article Content
Abstract
Objectives: The aims of our study were to evaluate the response rate, progression-free survival (PFS) and tolerate of concurrent chemoradiotherapy of Cisplatin-Vinorebine(oral) regimen in stage III non-small-cell lung cancer patients. Patients and Methods: In this cross-sectional study, we enrolled 48 patients with stage III non-small-cell lung cancer (according to the AJCC 2017 classification) who had a good performance status (PS of 0-1) at National cancer hospital and Nghe An oncology hospital. These patients were treated with a combination of radiation therapy and chemotherapy, consisting of Cisplatin and oral Vinorelbine. Result: Mean of age is 60,32; Male/Female rate is 42/6. The overall respone rate was 58,3% and the median PFS was 8,2 months. On multivariate analyses, prolonged radiation treatment time of more than 14 days and adenocarcinoma pathology were 2 independent factor that decrease respond rate. Prolonged radiation also associated with a decreased PFS. Common toxicities are leukopenia (54,2%), pneumonia(45,8) and post-radiation dermatitis (54,2%), most of which are grade 1,2. Summary: Concurrent chemoradiotherapy with regimen of Cisplatin and oral Vinorelbine for patients stage III NSCLC elicited favorable response rates and progression-free survival outcomes.
Article Details
Keywords
non-small cell lung cancer, stage III, chemoradiation, Cisplatin and oral Vinorelbine
References
2. Fukuoka K, Arioka H, Iwamoto Y, et al. Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer Amst Neth. 2001;34(3):451-460. doi:10.1016/s0169-5002(01)00265-3.
3. Yang Y, Chang J, Huang C, et al. A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer. J Thorac Dis. 2019;11(8):3347-3359. doi:10.21037/jtd.2019.08.22.
4. Isla D, De Las Peñas R, Insa A, et al. Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study). Lung cancer (Amsterdam, Netherlands). Sep 2019;135:161-168.
5. Senan S, Brade A, Wang LH, et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Mar 20 2016;34(9):953-962.
6. Lesueur P, Martel-Laffay I, Escande A, et al. Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review. Expert Review of Anticancer Therapy. 2018/11/02 2018;18(11):1159-1165.
7. McMillan MT, Ojerholm E, Verma V, et al. Radiation Treatment Time and Overall Survival in Locally Advanced Non-small Cell Lung Cancer. International journal of radiation oncology, biology, physics. Aug 1 2017;98(5):1142-1152.
8. Naito Y, Kubota K, Nihei K, et al. Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2008;3(6):617-622. doi:10.1097/JTO.0b013e3181753b38.